INVESTALGA AHTI S.L.

investalga.com

INVESTALGA is a Spanish innovative biotech specializing in the production of high quality bioactive compounds from green seaweeds available for use in nutrition, personal care and health markets. We are developing a scientific-technical-industrial base combining various disciplines: biotechnology, marine ecology, aquaculture, chemistry, nutrition and medicine, to credit and put value to the numerous possibilities derived from the unique biochemical composition of green seaweeds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More

CELL AND GENE THERAPY

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

news image

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

news image

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

news image

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More
news image

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More
news image

CELL AND GENE THERAPY

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More
news image

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More
news image

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More